[ad_1]
AstraZeneca released a statement on Monday defending its COVID-19 vaccine after some countries worried about blood clots in those vaccinated and called for a temporary suspension.
The company said there was “no evidence of an increased risk” of blood clots after receiving his injection.
Ireland said on Sunday it would temporarily suspend distribution of the vaccine “out of caution,” Reuters reported. The move was announced after reports of blood clotting in some of the recipients in Norway.
AstraZeneca, the Cambridge, UK company, said more than 17 million people had been vaccinated with the vaccine in the EU and UK, and that there was “no evidence of ‘increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia., in any particular age group, sex, lot or country. “
The statement highlighted cases of pulmonary embolism and said the number of such cases after receiving the vaccine is “much lower than one would naturally expect in a general population of this size and is similar for other authorized COVID-19 vaccines. “
The Netherlands followed Ireland on Sunday evening and announced they were suspending vaccinations with AstraZeneca as a precautionary measure for two weeks. The health ministry said the move followed six new reports in Denmark and Norway of blood clotting and lowering of blood platelet levels in people under the age of 50.
DENMARK SUSPENS USE OF ASTRAZENECA COVID-19 VACCINE FOLLOWING REPORTS OF BLOOD CLOTS
The Dutch pharmaceutical authority also pointed out that no link has been proven between the cases and the vaccine.
CLICK HERE TO GET THE FOX NEWS APP
The World Health Organization and the European Union’s medicines regulator have previously said there is no link between jab and an increased risk of developing a clot.
The Associated Press contributed to this report
[ad_2]
Source link